[1]
|
Younossi, Z.M., Golabi, P., Paik, J.M., Henry, A., Van Dongen, C. and Henry, L. (2023) The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review. Hepatol-ogy, 77, 1335-1347. https://doi.org/10.1097/HEP.0000000000000004
|
[2]
|
Radu, F., Potcovaru, C.-G., Salmen, T., Filip, P.V., Pop, C. and Fierbințeanu-Braticievici, C. (2023) The Link between NAFLD and Metabolic Syndrome. Di-agnostics, 13, Article No. 614. https://doi.org/10.3390/diagnostics13040614
|
[3]
|
Cai, J., Zhang, X.-J., Ji, Y.-X., Zhang, P., She, Z.-G. and Li, H. (2020) Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circulation Research, 126, 679-704.
https://doi.org/10.1161/CIRCRESAHA.119.316337
|
[4]
|
Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C.D. and Targher, G. (2020) Complications, Morbidity and Mortality of Nonalcoholic Fatty Liver Disease. Metabolism: Clinical and Experimental, 111, Article ID: 154170.
https://doi.org/10.1016/j.metabol.2020.154170
|
[5]
|
Motamed, N., Rabiee, B., Poustchi, H., Dehestani, B., Hemasi, G.R., Khonsari, M.R., Maadi, M., Saeedian, F.S. and Zamani, F. (2017) Non-Alcoholic Fatty Liver Disease (NAFLD) and 10-Year Risk of Cardiovascular Diseases. Clinics and Research in Hepatology and Gastroenterology, 41, 31-38. https://doi.org/10.1016/j.clinre.2016.07.005
|
[6]
|
Simon, T.G., Roelstraete, B., Hagström, H., Sundström, J. and Ludvigsson, J.F. (2022) Non-Alcoholic Fatty Liver Disease and Incident Major Adverse Cardiovascular Events: Results from a Nationwide Histology Cohort. Gut, 71, 1867-1875. https://doi.org/10.1136/gutjnl-2021-325724
|
[7]
|
Azzu, V., Vacca, M., Virtue, S., Allison, M. and Vidal-Puig, A. (2020) Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. Gastroenterology, 158, 1899-1912.
https://doi.org/10.1053/j.gastro.2019.12.054
|
[8]
|
Rosso, C., Kazankov, K., Younes, R., Esmaili, S., Marietti, M., Sacco, M., Carli, F., Gaggini, M., Salomone, F., Møller, H.J., et al. (2019) Crosstalk between Adipose Tissue Insulin Resistance and Liver Macrophages in Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 71, 1012-1021. https://doi.org/10.1016/j.jhep.2019.06.031
|
[9]
|
Wang, Y., Guo, X., Zhang, Y., Zhang, R. and Li, J. (2023) Differ-ent Associations of General and Abdominal Obesity with Upper and Lower Extremity Artery Disease among a Commu-nity Population in China. Nutrition & Metabolism, 20, Article No. 14. https://doi.org/10.1186/s12986-023-00736-1
|
[10]
|
Sakurai, Y., Kubota, N., Yamauchi, T. and Kadowaki, T. (2021) Role of Insulin Resistance in MAFLD. International Journal of Molecular Sciences, 22, Article No. 4156. https://doi.org/10.3390/ijms22084156
|
[11]
|
Deprince, A., Haas, J.T. and Staels, B. (2020) Dysregulated Lipid Me-tabolism Links NAFLD to Cardiovascular Disease. Molecular Metabolism, 42, Article ID: 101092. https://doi.org/10.1016/j.molmet.2020.101092
|
[12]
|
Geng, Y., Faber, K.N., de Meijer, V.E., Blokzijl, H. and Moshage, H. (2021) How Does Hepatic Lipid Accumulation Lead to Lipotoxicity in Non-Alcoholic Fatty Liver Disease? Hepatology International, 15, 21-35.
https://doi.org/10.1007/s12072-020-10121-2
|
[13]
|
Badmus, O.O., Hillhouse, S.A., Anderson, C.D., Hinds, T.D. and Stec, D.E. (2022) Molecular Mechanisms of Metabolic Associated Fatty Liver Disease (MAFLD): Functional Anal-ysis of Lipid Metabolism Pathways. Clinical Science, 136, 1347-1366. https://doi.org/10.1042/CS20220572
|
[14]
|
Beckner, M.E., Thompson, L., Radcliffe, P.N., Cherian, R., Wilson, M., Barringer, N., Margolis, L.M. and Karl, J.P. (2023) Sex Differences in Body Composition and Serum Metabolome Re-sponses to Sustained, Physical Training Suggest Enhanced Fat Oxidation in Women Compared with Men. Physiological Genomics, 55, 235-247.
https://doi.org/10.1152/physiolgenomics.00180.2022
|
[15]
|
Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M. and Sanyal, A.J. (2018) Mechanisms of NAFLD Development and Therapeutic Strategies. Nature Medicine, 24, 908-922. https://doi.org/10.1038/s41591-018-0104-9
|
[16]
|
Dabravolski, S.A., Bezsonov, E.E., Baig, M.S., Popkova, T.V. and Orekhov, A.N. (2021) Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases. Internation-al Journal of Molecular Sciences, 22, Article No. 6949. https://doi.org/10.3390/ijms22136949
|
[17]
|
Incalza, M.A., D’Oria, R., Natalicchio, A., Perrini, S., Laviola, L. and Giorgino, F. (2018) Oxidative Stress and Reactive Oxygen Spe-cies in Endothelial Dysfunction Associated with Cardiovascular and Metabolic Diseases. Vascular Pharmacology, 100, 1-19. https://doi.org/10.1016/j.vph.2017.05.005
|
[18]
|
Hoebinger, C., Rajcic, D. and Hendrikx, T. (2021) Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis. Frontiers in Cardio-vascular Medicine, 8, Article 824481.
https://doi.org/10.3389/fcvm.2021.824481
|
[19]
|
Liu, S., Wang, J., Wu, S., Niu, J., Zheng, R., Bie, L., Xin, Z., Wang, S., Lin, H., Zhao, Z., et al. (2021) The Progression and Regression of Metabolic Dysfunction-Associated Fatty Liver Disease Are Associated with the Development of Subclinical Atherosclerosis: A Prospective Analysis. Metabolism: Clinical and Experimental, 120, Article ID: 154779.
https://doi.org/10.1016/j.metabol.2021.154779
|
[20]
|
Zewinger, S., Reiser, J., Jankowski, V., Alansary, D., Hahm, E., Triem, S., Klug, M., Schunk, S.J., Schmit, D., Kramann, R., et al. (2020) Apolipoprotein C3 Induces Inflammation and Organ Damage by Alternative Inflammasome Activation. Nature Immunology, 21, 30-41. https://doi.org/10.1038/s41590-019-0548-1
|
[21]
|
Tripodi, A., Lombardi, R., Primignani, M., La Mura, V., Peyvandi, F. and Fracanzani, A.L. (2022) Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Caus-es and Consequences. Biomedicines, 10, Article No. 249. https://doi.org/10.3390/biomedicines10020249
|
[22]
|
Di Minno, M.N., Tufano, A., Rusolillo, A., Di Minno, G. and Tarantino, G. (2010) High Prevalence of Nonalcoholic Fatty Liver in Patients with Idiopathic Venous Thromboembolism. World Journal of Gastroenterology, 16, 6119-6122.
https://doi.org/10.3748/wjg.v16.i48.6119
|
[23]
|
Drożdż, K., Nabrdalik, K., Hajzler, W., Kwiendacz, H., Gumprecht, J. and Lip, G.Y.H. (2021) Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. Nutrients, 14, Article No. 103. https://doi.org/10.3390/nu14010103
|
[24]
|
Mouries, J., Brescia, P., Silvestri, A., Spadoni, I., Sorribas, M., Wiest, R., Mileti, E., Galbiati, M., Invernizzi, P., Adorini L., et al. (2019) Microbiota-Driven Gut Vascular Barrier Disruption Is a Prerequisite for Non-Alcoholic Steatohepatitis Development. Journal of Hepatology, 71, 1216-1228. https://doi.org/10.1016/j.jhep.2019.08.005
|
[25]
|
Gottlieb, A. and Canbay, A. (2019) Why Bile Acids Are So Im-portant in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression. Cells, 8, Article No. 1358. https://doi.org/10.3390/cells8111358
|
[26]
|
De Munck, T.J.I., Xu, P., Verwijs, H.J.A., Masclee, A.A.M., Jonkers, D., Verbeek, J. and Koek, G.H. (2020) Intestinal Permeability in Human Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Liver International, 40, 2906-2916. https://doi.org/10.1111/liv.14696
|
[27]
|
Sookoian, S. and Pirola, C.J. (2021) Liver Tissue Microbiota in Nonalcoholic Liver Disease: A Change in the Paradigm of Host-Bacterial Interactions. Hepatobiliary Surgery and Nutrition, 10, 337-349.
https://doi.org/10.21037/hbsn-20-270
|
[28]
|
Kolodziejczyk, A.A., Zheng, D., Shibolet, O. and Elinav, E. (2019) The Role of the Microbiome in NAFLD and NASH. EMBO Molecular Medicine, 11, e9302. https://doi.org/10.15252/emmm.201809302
|
[29]
|
Libby, P. (2021) The Changing Landscape of Atherosclerosis. Nature, 592, 524-533.
https://doi.org/10.1038/s41586-021-03392-8
|
[30]
|
Li, F., Ye, J., Shao, C. and Zhong, B. (2021) Compositional Al-terations of Gut Microbiota in Nonalcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. Li-pids in Health and Disease, 20, Article No. 22.
https://doi.org/10.1186/s12944-021-01440-w
|
[31]
|
Anto, L. and Blesso, C.N. (2022) Interplay between Diet, the Gut Microbiome, and Atherosclerosis: Role of Dysbiosis and Microbial Metabolites on Inflammation and Disordered Li-pid Metabolism. The Journal of Nutritional Biochemistry, 105, Article ID: 108991. https://doi.org/10.1016/j.jnutbio.2022.108991
|
[32]
|
Tang, W.H., Wang, Z., Levison, B.S., Koeth, R.A., Britt, E.B., Fu, X., Wu, Y. and Hazen, S.L. (2013) Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk. The New England Journal of Medicine, 368, 1575-1584. https://doi.org/10.1056/NEJMoa1109400
|
[33]
|
Zhang, H., Jing, L., Zhai, C., Xiang, Q., Tian, H. and Hu, H. (2023) Intestinal Flora Metabolite Trimethylamine Oxide Is Inextrica-bly Linked to Coronary Heart Disease. Journal of Cardiovascular Pharmacology, 81, 175-182.
https://doi.org/10.1097/FJC.0000000000001387
|
[34]
|
Zhou, D., Zhang, J., Xiao, C., Mo, C. and Ding, B.S. (2022) Trimethylamine-N-Oxide (TMAO) Mediates the Crosstalk between the Gut Microbiota and Hepatic Vascular Niche to Alleviate Liver Fibrosis in Nonalcoholic Steatohepatitis. Frontiers in Immunology, 13, Article 964477. https://doi.org/10.3389/fimmu.2022.964477
|
[35]
|
Luo, F., Oldoni, F. and Das, A. (2022) TM6SF2: A Novel Ge-netic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease. Hepatology Communications, 6, 448-460. https://doi.org/10.1002/hep4.1822
|
[36]
|
Xue, W.-Y., Zhang, L., Liu, C.-M., Gao, Y., Li, S.-J., Huai, Z.-Y., Dai, J. and Wang, Y.-Y. (2022) Research Progress on the Relationship between TM6SF2 rs58542926 Polymorphism and Non-Alcoholic Fatty Liver Disease. Expert Review of Gastroenterology & Hepatology, 16, 97-107. https://doi.org/10.1080/17474124.2022.2032661
|
[37]
|
Luukkonen, P.K., Qadri, S., Lehtimäki, T.E., Juuti, A., Sammalkorpi, H., Penttilä, A.K., Hakkarainen, A., Orho-Melander, M., Arola, J. and Yki-Järvinen, H. (2021) The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-Resistant Patients. The Journal of Clinical Endocrinology and Metabolism, 106, e300-e315.
https://doi.org/10.1210/clinem/dgaa729
|
[38]
|
Ren, Z., Simons, P., Wesselius, A., Stehouwer, C.D.A. and Brouwers, M. (2023) Relationship between NAFLD and Coronary Artery Disease: A Mendelian Randomization Study. Hepatology, 77, 230-238.
https://doi.org/10.1002/hep.32534
|
[39]
|
Wu, C., Zhang, K., Odden, M.C., Kucharska-Newton, A.M., Palta, P., Matsushita, K., Gottesman, R.F. and Windham, B.G. (2021) Subclinical Vascular Disease Burden and Premature Mortal-ity among Middle-Aged Adults: The Atherosclerosis Risk in Communities Study. Journal of General Internal Medicine, 36, 2048-2054.
https://doi.org/10.1007/s11606-020-06398-6
|
[40]
|
Fernández-Friera, L., Peñalvo, J.L., Fernández-Ortiz, A., Ibañez, B., López-Melgar, B., Laclaustra, M., Oliva, B., Mocoroa, A., Mendiguren, J., Martínez de Vega, V., et al. (2015) Prev-alence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation, 131, 2104-2113. https://doi.org/10.1161/CIRCULATIONAHA.114.014310
|
[41]
|
Xu, S., Ilyas, I., Little, P.J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) Endothelial Dysfunction in Atherosclerotic Cardiovascular Dis-eases and Beyond: From Mechanism to Pharmacotherapies. Pharmacological Reviews, 73, 924-967. https://doi.org/10.1124/pharmrev.120.000096
|
[42]
|
Corretti, M.C., Anderson, T.J., Benjamin, E.J., Celermajer, D., Charbonneau, F., Creager, M.A., Deanfield, J., Drexler, H., Gerhard-Herman, M., Herrington, D., et al. (2002) Guide-lines for the Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery: A Report of the International Brachial Artery Reactivity Task Force. Journal of the American College of Cardiology, 39, 257-265.
https://doi.org/10.1016/S0735-1097(01)01746-6
|
[43]
|
Villanova, N., Moscatiello, S., Ramilli, S., Bugianesi, E., Magalotti, D., Vanni, E., Zoli, M. and Marchesini, G. (2005) Endothelial Dysfunction and Cardiovascular Risk Profile in Nonalcoholic Fatty Liver Disease. Hepatology, 42, 473-480. https://doi.org/10.1002/hep.20781
|
[44]
|
Al-Hamoudi, W., Alsadoon, A., Hassanian, M., Alkhalidi, H., Abdo, A., Nour, M., Halwani, R., Sanai, F., Alsharaabi, A., Alswat, K., et al. (2020) Endothelial Dysfunction in Nonalcoholic Steatohepatitis with Low Cardiac Disease Risk. Scientific Reports, 10, Article No. 8825. https://doi.org/10.1038/s41598-020-65835-y
|
[45]
|
Vatner, S.F., Zhang, J., Vyzas, C., Mishra, K., Graham, R.M. and Vatner, D.E. (2021) Vascular Stiffness in Aging and Disease. Frontiers in Physiology, 12, Article 762437. https://doi.org/10.3389/fphys.2021.762437
|
[46]
|
Duprez, D.A. (2012) Arterial Stiffness/Elasticity in the Contribution to Progression of Heart Failure. Heart Failure Clinics, 8, 135-141. https://doi.org/10.1016/j.hfc.2011.08.001
|
[47]
|
Vasan, R.S., Pan, S., Xanthakis, V., Beiser, A., Larson, M.G., Seshadri, S. and Mitchell, G.F. (2022) Arterial Stiffness and Long-Term Risk of Health Outcomes: The Framingham Heart Study. Hypertension, 79, 1045-1056.
https://doi.org/10.1161/HYPERTENSIONAHA.121.18776
|
[48]
|
Yu, S. and McEniery, C.M. (2020) Central ver-sus Peripheral Artery Stiffening and Cardiovascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 40, 1028-1033. https://doi.org/10.1161/ATVBAHA.120.313128
|
[49]
|
Segers, P., Rietzschel, E.R. and Chirinos, J.A. (2020) How to Measure Arterial Stiffness in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 40, 1034-1043. https://doi.org/10.1161/ATVBAHA.119.313132
|
[50]
|
Huang, Y., Bi, Y., Xu, M., Ma, Z., Xu, Y., Wang, T., Li, M., Liu, Y., Lu, J., Chen, Y., et al. (2012) Nonalcoholic Fatty Liver Disease Is Associated with Athero-sclerosis in Middle-Aged and Elderly Chinese. Arteriosclerosis, Thrombosis, and Vascular Biology, 32, 2321-2326. https://doi.org/10.1161/ATVBAHA.112.252957
|
[51]
|
Jaruvongvanich, V., Chenbhanich, J., Sanguankeo, A., Rat-tanawong, P., Wijarnpreecha, K. and Upala, S. (2017) Increased Arterial Stiffness in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. European Journal of Gastroenterology & Hepatology, 29, e28-e35. https://doi.org/10.1097/MEG.0000000000000909
|
[52]
|
Willeit, P., Tschiderer, L., Allara, E., Reuber, K., Seekircher, L., Gao, L., Liao, X., Lonn, E., Gerstein, H.C., Yusuf, S., et al. (2020) Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. Circulation, 142, 621-642.
https://doi.org/10.1161/CIRCULATIONAHA.120.046361
|
[53]
|
Tang, A.S.P., Chan, K.E., Quek, J., Xiao, J., Tay, P., Teng, M., Lee, K.S., Lin, S.Y., Myint, M.Z., Tan, B., et al. (2022) Non-Alcoholic Fatty Liver Disease Increases Risk of Carotid Atherosclerosis and Ischemic Stroke: An Updated Meta-Analysis with 135,602 Individuals. Clinical and Mo-lecular Hepatology, 28, 483-496.
https://doi.org/10.3350/cmh.2021.0406
|
[54]
|
Arai, T., Atsukawa, M., Tsubota, A., Kato, K., Abe, H., Ono, H., Kawano, T., Yoshida, Y., Tanabe, T., Okubo, T., et al. (2021) Liver Fibrosis Is Associated with Carotid Atherosclerosis in Patients with Liver Biopsy-Proven Nonalcoholic Fatty Liver disease. Scientific Reports, 11, Article No. 15938. https://doi.org/10.1038/s41598-021-95581-8
|
[55]
|
Arai, T., Atsukawa, M., Tsubota, A., Kawano, T., Koeda, M., Yoshida, Y., Tanabe, T., Okubo, T., Hayama, K., Iwashita, A., et al. (2019) Factors Influencing Subclinical Atheroscle-rosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. PLOS ONE, 14, e0224184. https://doi.org/10.1371/journal.pone.0224184
|
[56]
|
Di Costanzo, A., D’Erasmo, L., Polimeni, L., Baratta, F., Coletta, P., Di Martino, M., Loffredo, L., Perri, L., Ceci, F., Montali, A., et al. (2017) Non-Alcoholic Fatty Liver Disease and Subclinical Atherosclerosis: A Comparison of metabolically- versus Genetically-Driven Excess Fat Hepatic Storage. Atherosclerosis, 257, 232-239.
https://doi.org/10.1016/j.atherosclerosis.2016.12.018
|
[57]
|
Alexander, M., Loomis, A.K., van der Lei, J., Du-arte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., Mosseveld, M., et al. (2019) Non-Alcoholic Fatty Liver Disease and Risk of Incident Acute Myocardial Infarction and Stroke: Findings from Matched Cohort Study of 18 Million European Adults. BMJ, 367, Article No. l5367. https://doi.org/10.1136/bmj.l5367
|
[58]
|
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Askling, J., Hultcrantz, R. and Kechagias, S. (2019) Cardiovascular Risk Factors in Non-Alcoholic Fatty Liver Disease. Liver Inter-national, 39, 197-204.
https://doi.org/10.1111/liv.13973
|
[59]
|
Wong, V.W.-S., Wong, G.L.-H., Yeung, J.C.-L., Fung, C.Y.-K., Chan, J.K.-L., Chang, Z.H.-Y., Kwan, C.T.-Y., Lam, H.-W., Limquiaco, J., Chim, A.M.-L., et al. (2016) Long-Term Clinical Outcomes after Fatty Liver Screening in Patients Undergoing Coronary Angiogram: A Prospective Cohort Study. Hepa-tology, 63, 754-763.
https://doi.org/10.1002/hep.28253
|
[60]
|
Hsu, P.-F., Wang, Y.-W., Lin, C.-C., Wang, Y.-J., Ding, Y.-Z., Liou, T.-L., Huang, S.-S., Lu, T.-M., Chan, W.-L., Lin, S.-J., et al. (2021) The Association of the Steatosis Severity in Fatty Liver Disease with Coronary Plaque Pattern in General Population. Liver International, 41, 81-90. https://doi.org/10.1111/liv.14637
|
[61]
|
Keskin, M., Hayıroğlu, M., Uzun, A.O., Güvenç, T.S., Şahin, S. and Kozan, Ö. (2017) Effect of Nonalcoholic Fatty Liver Disease on in-Hospital and Long-Term Outcomes in Patients with ST-Segment Elevation Myocardial Infarction. The American Journal of Cardiology, 120, 1720-1726. https://doi.org/10.1016/j.amjcard.2017.07.107
|
[62]
|
Chen, Y., Xu, M., Wang, T., Sun, J., Sun, W., Xu, B., Huang, X., Xu, Y., Lu, J., Li, X., et al. (2015) Advanced Fibrosis Associates with Atherosclerosis in Subjects with Nonalcoholic Fatty Liver Disease. Atherosclerosis, 241, 145-150.
https://doi.org/10.1016/j.atherosclerosis.2015.05.002
|
[63]
|
Mantovani, A., Dauriz, M., Sandri, D., Bonapace, S., Zoppini, G., Tilg, H., Byrne, C.D. and Targher, G. (2019) Association between Non-Alcoholic Fatty Liver Disease and Risk of Atrial Fibrillation in Adult Individuals: An Updated Meta-Analysis. Liver International, 39, 758-769. https://doi.org/10.1111/liv.14044
|
[64]
|
Mantovani, A., Csermely, A., Taverna, A., Cappelli, D., Benfari, G., Bona-pace, S., Byrne, C.D. and Targher, G. (2023) Association between Metabolic Dysfunction-Associated Fatty Liver Dis-ease and Supraventricular and Ventricular Tachyarrhythmias in Patients with Type 2 Diabetes. Diabetes & Metabolism, 49, Article ID: 101416.
https://doi.org/10.1016/j.diabet.2022.101416
|
[65]
|
Mantovani, A., Rigolon, R., Pichiri, I., Bonapace, S., Morani, G., Zoppini, G., Bonora, E. and Targher, G. (2017) Nonalcoholic Fatty Liver Disease Is Associated with an Increased Risk of Heart Block in Hospitalized Patients with Type 2 Diabetes Mellitus. PLOS ONE, 12, e0185459. https://doi.org/10.1371/journal.pone.0185459
|
[66]
|
Chen, Z., Liu, J., Zhou, F., Li, H., Zhang, X.-J., She, Z.-G., Lu, Z., Cai, J. and Li, H. (2021) Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. Circulation Research, 128, 1747-1765.
https://doi.org/10.1161/CIRCRESAHA.121.319059
|
[67]
|
Whitsett, M., Wilcox, J., Yang, A., Zhao, L., Rinella, M. and VanWagner, L.B. (2019) Atrial Fibrillation Is Highly Prevalent yet Undertreated in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis. Liver International, 39, 933-940. https://doi.org/10.1111/liv.14018
|
[68]
|
Bonapace, S., Valbusa, F., Bertolini, L., Pichiri, I., Mantovani, A., Rossi, A., Zenari, L., Barbieri, E. and Targher, G. (2014) Nonalco-holic Fatty Liver Disease Is Associated with Aortic Valve Sclerosis in Patients with Type 2 Diabetes Mellitus. PLOS ONE, 9, e88371. https://doi.org/10.1371/journal.pone.0088371
|
[69]
|
Mantovani, A., Pernigo, M., Bergamini, C., Bonapace, S., Lipari, P., Valbusa, F., Bertolini, L., Zenari, L., Pichiri, I., Dauriz, M., et al. (2015) Heart Valve Calcifica-tion in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Metabolism: Clinical and Experimental, 64, 879-887. https://doi.org/10.1016/j.metabol.2015.04.003
|
[70]
|
Anstee, Q.M., Mantovani, A., Tilg, H. and Targher, G. (2018) Risk of Cardiomyopathy and Cardiac Arrhythmias in Patients with Nonalcoholic Fatty Liver Disease. Nature Re-views Gastroenterology & Hepatology, 15, 425-439.
https://doi.org/10.1038/s41575-018-0010-0
|
[71]
|
Lee, Y.-H., Kim, K.-J., Yoo, M.-E., Kim, G., Yoon, H.-J., Jo, K., Youn, J.-C., Yun, M., Park, J.Y., Shim, C.Y., et al. (2018) Association of Non-Alcoholic Steatohepatitis with Subclini-cal Myocardial Dysfunction in Non-Cirrhotic Patients. Journal of Hepatology, 68, 764-772. https://doi.org/10.1016/j.jhep.2017.11.023
|
[72]
|
Petta, S., Argano, C., Colomba, D., Cammà, C., Di Marco, V., Cabibi, D., Tuttolomondo, A., Marchesini, G., Pinto, A., Licata, G., et al. (2015) Epicardial Fat, Cardiac Geometry and Cardiac Function in Patients with Non-Alcoholic Fatty Liver Disease: Association with the Severity of Liver Disease. Journal of Hepatology, 62, 928-933.
https://doi.org/10.1016/j.jhep.2014.11.030
|
[73]
|
VanWagner, L.B., Wilcox, J.E., Colangelo, L.A., Lloyd-Jones, D.M., Carr, J.J., Lima, J.A., Lewis, C.E., Rinella, M.E. and Shah, S.J. (2015) Association of Nonalcoholic Fatty Liver Disease with Subclinical Myocardial Remodeling and Dysfunction: A Population-Based Study. Hepatology, 62, 773-783. https://doi.org/10.1002/hep.27869
|
[74]
|
Lauridsen, B.K., Stender, S., Kristensen, T.S., Kofoed, K.F., Køber, L., Nordestgaard, B.G. and Tybjærg-Hansen, A. (2018) Liver Fat Content, Non-Alcoholic Fatty Liver Disease, and Is-chaemic Heart Disease: Mendelian Randomization and Meta-Analysis of 279 013 Individuals. European Heart Journal, 39, 385-393.
https://doi.org/10.1093/eurheartj/ehx662
|
[75]
|
Bisaccia, G., Ricci, F., Khanji, M.Y., Sorella, A., Melchiorre, E., Iannetti, G., Galanti, K., Mantini, C., Pizzi, A.D., Tana, C., et al. (2023) Cardiovascular Morbidity and Mortality Related to Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Current Problems in Cardiology, 48, Article ID: 101643.
https://doi.org/10.1016/j.cpcardiol.2023.101643
|
[76]
|
Abdeldyem, S.M., Goda, T., Khodeir, S.A., Abou Saif, S. and Abd-Elsalam, S. (2017) Nonalcoholic Fatty Liver Disease in Patients with Acute Ischemic Stroke Is Associated with More Severe Stroke and Worse Outcome. Journal of Clinical Lipidology, 11, 915-919. https://doi.org/10.1016/j.jacl.2017.04.115
|
[77]
|
Kim, G., Kim, K.J., Rhee, Y. and Lim, S.K. (2017) Significant Liver Fibrosis Assessed Using Liver Transient Elastography Is Independently Associated with Low Bone Mineral Density in Patients with Non-Alcoholic Fatty Liver Disease. PLOS ONE, 12, e0182202. https://doi.org/10.1371/journal.pone.0182202
|
[78]
|
Wu, M., Zha, M., Lv, Q., Xie, Y., Yuan, K., Zhang, X. and Liu, X. (2022) Non-Alcoholic Fatty Liver Disease and Stroke: A Mendelian Randomization Study. European Journal of Neurology, 29, 1534-1537.
https://doi.org/10.1111/ene.15277
|
[79]
|
Li, H., Hu, B., Wei, L., Zhou, L., Zhang, L., Lin, Y., Qin, B., Dai, Y. and Lu, Z. (2018) Non-Alcoholic Fatty Liver Disease Is Associated with Stroke Severity and Progression of Brainstem In-farctions. European Journal of Neurology, 25, 577-e34. https://doi.org/10.1111/ene.13556
|
[80]
|
Byrne, C.D. and Targher, G. (2020) NAFLD as a Driver of Chronic Kidney Disease. Journal of Hepatology, 72, 785-801. https://doi.org/10.1016/j.jhep.2020.01.013
|
[81]
|
Liang, Y., Chen, H., Liu, Y., Hou, X., Wei, L., Bao, Y., Yang, C., Zong, G., Wu, J. and Jia, W. (2022) Association of MAFLD with Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China. The Journal of Clinical Endocrinology and Metabolism, 107, 88-97. https://doi.org/10.1210/clinem/dgab641
|
[82]
|
Wang, T.-Y., Wang, R.-F., Bu, Z.-Y., Targher, G., Byrne, C.D., Sun, D.-Q. and Zheng, M.-H. (2022) Association of Metabolic Dysfunction-Associated Fatty Liver Disease with Kidney Disease. Nature Reviews Nephrology, 18, 259-268.
https://doi.org/10.1038/s41581-021-00519-y
|
[83]
|
Yeung, M.-W., Wong, G.L.-H., Choi, K.C., Luk, A.O., Kwok, R., Shu, S.S., Chan, A.W., Lau, E.S.H., Ma, R.C.W., Chan, H.L., et al. (2017) Advanced Liver Fibrosis but Not Steato-sis Is Independently Associated with Albuminuria in Chinese Patients with Type 2 Diabetes. Journal of Hepatology, 68, 147-156. https://doi.org/10.1016/j.jhep.2017.09.020
|
[84]
|
Eslam, M., Newsome, P.N., Sarin, S.K., Anstee, Q.M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wong, V. W.-S., Dufour, J.F., Schattenberg, J.M., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209.
https://doi.org/10.1016/j.jhep.2020.03.039
|
[85]
|
Chitturi, S., Wong, V.W.-S., Chan, W.-K., Wong, G.L.-H., Wong, S.K.-H., Sollano, J., Ni, Y.-H., Liu, C.-J., Lin, Y.-C., Lesmana, L.-A., et al. (2018) The Asia-Pacific Working Party on Non-Alcoholic Fatty Liver Disease Guidelines 2017-Part 2: Management and Special Groups. Journal of Gastroenter-ology and Hepatology, 33, 86-98.
https://doi.org/10.1111/jgh.13856
|
[86]
|
Chalasani, N., Younossi, Z., Lavine, J.E., Charlton, M., Cusi, K., Rinella, M., Harrison, S.A., Brunt, E.M. and Sanyal, A.J. (2018) The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 67, 328-357. https://doi.org/10.1002/hep.29367
|
[87]
|
Paul, S. and Davis, A.M. (2018) Diagnosis and Management of Nonalco-holic Fatty Liver Disease. JAMA, 320, 2474-2475. https://doi.org/10.1001/jama.2018.17365
|
[88]
|
Vilar-Gomez, E., Calzadilla-Bertot, L., Wong, V.W.-S., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Sanz, M.A.-Q., Conde-Martin, A.F., et al. (2018) Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients with Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology, 155, 443-457. https://doi.org/10.1053/j.gastro.2018.04.034
|
[89]
|
Taylor, R.S., Taylor, R.J., Bay-liss, S., Hagström, H., Nasr, P., Schattenberg, J.M., Ishigami, M., Toyoda, H., Wong, V.W.-S., Peleg, N., et al. (2020) Association between Fibrosis Stage and Outcomes of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Re-view and Meta-Analysis. Gastroenterology, 158, 1611-1625.
https://doi.org/10.1053/j.gastro.2020.01.043
|
[90]
|
Ravaioli, F., Dajti, E., Mantovani, A., Newsome, P.N., Targher, G. and Colecchia, A. (2023) Diagnostic Accuracy of FibroScan-AST (FAST) Score for the Non-Invasive Identification of Patients with Fibrotic Non-Alcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. Gut, 72, 1399-1409. https://doi.org/10.1136/gutjnl-2022-328689
|
[91]
|
Mózes, F.E., Lee, J.A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R.E., Holleboom, A.G., van Dijk, A.M., et al. (2023) Performance of Non-Invasive Tests and Histology for the Prediction of Clinical Outcomes in Patients with Non-Alcoholic Fatty Liver Disease: An Individual Participant Data Meta-Analysis. The Lancet Gastroenterology & Hepatology, 8, 704-713. https://doi.org/10.1016/S2468-1253(23)00141-3
|
[92]
|
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R. and Kechagias, S. (2017) Fibrosis Stage but not NASH Predicts Mortality and Time to Development of Severe Liver Disease in Biopsy-Proven NAFLD. Journal of Hepatology, 67, 1265-1273. https://doi.org/10.1016/j.jhep.2017.07.027
|
[93]
|
Francque, S.M., van der Graaff, D. and Kwanten, W.J. (2016) Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk: Pathophysiological Mechanisms and Implications. Journal of Hepatology, 65, 425-443.
https://doi.org/10.1016/j.jhep.2016.04.005
|
[94]
|
Lee, D.S., Evans, J.C., Robins, S.J., Wilson, P.W., Albano, I., Fox, C.S., Wang, T.J., Benjamin, E.J., D’Agostino, R.B. and Vasan, R.S. (2007) Gamma Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality Risk: The Framingham Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 127-133.
https://doi.org/10.1161/01.ATV.0000251993.20372.40
|
[95]
|
Blond, E., Disse, E., Cuerq, C., Drai, J., Valette, P.J., Laville, M., Thivolet, C., Simon, C. and Caussy, C. (2017) EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease in Severely Obese People: Do They Lead to Over-Referral? Dia-betologia, 60, 1218-1222.
https://doi.org/10.1007/s00125-017-4264-9
|
[96]
|
Kwon, O.Y., Choi, J.Y. and Jang, Y. (2023) The Effectiveness of eHealth Interventions on Lifestyle Modification in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 25, e37487. https://doi.org/10.2196/37487
|
[97]
|
Alam, S., Jahid Hasan, M., Khan, M.A.S., Alam, M. and Hasan, N. (2019) Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient. Journal of Translational Internal Medicine, 7, 106-114. https://doi.org/10.2478/jtim-2019-0023
|
[98]
|
Hohenester, S., Christiansen, S., Nagel, J., Wimmer, R., Artmann, R., Denk, G., Bischoff, M., Bischoff, G. and Rust, C. (2018) Lifestyle Intervention for Morbid Obesity: Effects on Liver Steatosis, Inflammation, and Fibrosis. American Journal of Physiology Gastrointestinal and Liver Physiology, 315, G329-G338.
https://doi.org/10.1152/ajpgi.00044.2018
|
[99]
|
Golabi, P., Locklear, C.T., Austin, P., Afdhal, S., Byrns, M., Gerber, L. and Younossi, Z.M. (2016) Effectiveness of Exercise in Hepatic Fat Mobilization in Non-Alcoholic Fatty Liver Dis-ease: Systematic Review. World Journal of Gastroenterology, 22, 6318-6327. https://doi.org/10.3748/wjg.v22.i27.6318
|
[100]
|
Fernández, T., Viñuela, M., Vidal, C. and Barrera, F. (2022) Life-style Changes in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. PLOS ONE, 17, e0263931.
https://doi.org/10.1371/journal.pone.0263931
|
[101]
|
Gepner, Y., Shelef, I., Komy, O., Cohen, N., Schwarzfuchs, D., Bril, N., Rein, M., Serfaty, D., Kenigsbuch, S., Zelicha, H., et al. (2019) The Beneficial Effects of Mediterranean Diet over Low-Fat Diet May Be Mediated by Decreasing Hepatic Fat Content. Journal of Hepatology, 71, 379-388. https://doi.org/10.1016/j.jhep.2019.04.013
|
[102]
|
Dolce, A. and Torre, S.D. (2023) Sex, Nutrition, and NAFLD: Relevance of Environmental Pollution. Nutrients, 15, Article No. 2335. https://doi.org/10.3390/nu15102335
|